Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells ...

Heald’s money-back guarantee boldly links business success to patient outcomes,” said Dr. Neal Patel, CIO at Vanderbilt ...

Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information ...

Investors may submit written questions in advance of the conference call to [email protected] or through the webcast portal. A replay of the webcast will be available on the Company’s website at ...

RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: ...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study ; Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid- ...

Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024. New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024. CapsoCam Plus® ...

The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional ...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three ...

GTB-3650 TriKE ®  Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and ...

Ended the quarter with $4.8 million in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 ...

Second Quarter 2025 Financial Results Cash, cash equivalents, and marketable securities as of June 30, 2025, were $39.1 million, compared to $49.3 million as of March 31, 2025.